✒ BioNTech’s biggest-ever deal with an aim to expand beyond the Covid-19 vaccine that transformed its fortunes.

Commentary by FT:

“Success in the battle against Covid-19 does not ensure success against cancer, but should narrow the odds. While many innovative biotechs are struggling to raise funds, a successful coronavirus vaccine has left Moderna with about $7bn of net cash. BioNTech has double that. They gained cash and knowhow in the pandemic. That can now be applied to other urgent medical needs.”